As of 2022, around 42 percent of all Humira U.S. sales are expected to be at risk due to the drug patent expiring in 2023. This statistic illustrates the share of sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries.
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
Print the statistic including description and metadata.
Chart type
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Statista has been my savior on several occasions.
The site is easy to maneuver and the data is in a format that can
go right into a report or presentation.
Learn more about how Statista can support your business.
Evaluate Vantage. (May 25, 2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph]. In Statista. Retrieved February 25, 2025, from https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028." Chart. May 25, 2022. Statista. Accessed February 25, 2025. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. (2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028. Statista. Statista Inc.. Accessed: February 25, 2025. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales Share of Leading Pharmaceutical Products at Risk in The U.S. Due to Approaching Drug Patent Expiries between 2022 and 2028." Statista, Statista Inc., 25 May 2022, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage, Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 Statista, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/ (last visited February 25, 2025)
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph], Evaluate Vantage, May 25, 2022. [Online]. Available: https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.